Mast Cell Activation Syndrome
6
1
1
2
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 47/100
16.7%
1 terminated out of 6 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (6)
Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
Is Swimming a More Tolerable Form of Movement for Individuals With Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome?
Unhide® Project: A Digital Health Platform to Collect Lifestyle Data for Brain Inflammation Research
Masitinib for the Treatment of Severe Mast Cell Activation Syndrome
Ocular and Palpebral Manifestations of Mastocytosis (MOOMA)
Mast Cell Activation Test in Allergic Disease